APA (7th ed.) Citation

Driedger, J. H., Schröter, J., Hertzberg, C., Weschke, B., Kaindl, A. M., Lücke, T., . . . Saffari, A. (2025). Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT), a two-arm, randomized, observer-blind, controlled phase IIb national multicentre clinical trial: Study protocol. Orphanet journal of rare diseases, 20, . https://doi.org/10.1186/s13023-024-03495-1

Chicago Style (17th ed.) Citation

Driedger, Jan Henje, et al. "Long-term Neuropsychologic Outcome of Pre-emptive MTOR Inhibitor Treatment in Children with Tuberous Sclerosis Complex (TSC) Under 4 months of Age (PROTECT), a Two-arm, Randomized, Observer-blind, Controlled Phase IIb National Multicentre Clinical Trial: Study Protocol." Orphanet Journal of Rare Diseases 20 (2025). https://doi.org/10.1186/s13023-024-03495-1.

MLA (9th ed.) Citation

Driedger, Jan Henje, et al. "Long-term Neuropsychologic Outcome of Pre-emptive MTOR Inhibitor Treatment in Children with Tuberous Sclerosis Complex (TSC) Under 4 months of Age (PROTECT), a Two-arm, Randomized, Observer-blind, Controlled Phase IIb National Multicentre Clinical Trial: Study Protocol." Orphanet Journal of Rare Diseases, vol. 20, 2025, https://doi.org/10.1186/s13023-024-03495-1.